辅助化疗的副作用及其对老年乳腺癌患者预后的影响：一项队列研究
Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study.
作者信息
Zanuso Valentina, Fregoni Vittorio, Gervaso Lorenzo
机构信息
Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, 20089 Rozzano (MI), Italy.
Humanitas University, 20090 Pieve Emanuele (MI), Italy.
出版信息
Future Sci OA. 2020 Aug 10;6(9):FSO617. doi: 10.2144/fsoa-2020-0076.
AIM
Breast cancer patients over the age of 65 are more likely to suffer chemotherapy side effects, with premature discontinuation, which negatively affects survival.
METHODS
We conducted a retrospective cohort study enrolling breast cancer patients; dose reductions or interruptions of chemotherapy have been collected, as well as side effects. Progression-free survival was determined by Kaplan-Meier and evaluated for its association with reduction/suspension. The study included 128 women (median age: 71).
RESULTS
Nineteen patients experienced cardiotoxicity, while dosage of chemotherapy was reduced in 23 patients (18.0%), and 14 (10.9%) had premature interruptions. Dose reduction/interruptions were associated with numerically worse progression-free survival (78.2 vs 94.8 months; p = 0.10).
CONCLUSION
Reduction/discontinuation of chemotherapy due to side effects affected nearly 30% of our population, potentially worsening outcomes.
目的
65岁以上的乳腺癌患者更易出现化疗副作用，化疗提前中断会对生存率产生负面影响。
方法
我们开展了一项回顾性队列研究，纳入乳腺癌患者；收集化疗剂量减少或中断情况以及副作用。采用Kaplan-Meier法确定无进展生存期，并评估其与剂量减少/暂停的相关性。该研究纳入了128名女性（中位年龄：71岁）。
结果
19名患者出现心脏毒性，23名患者（18.0%）化疗剂量减少，14名患者（10.9%）化疗提前中断。剂量减少/中断与数值上较差的无进展生存期相关（78.2个月对94.8个月；p = 0.10）。
结论
因副作用减少/停止化疗影响了近30%的患者，可能使预后恶化。
Zotero 插件